Customer concentration
Historical revenue has been generated from a limited number of customers, increasing dependence on a few buyers.
- Scope
- One customer accounted for 92% of sales in a prior quarter
- Materiality
- high
Yubo International Biotech Ltd
Yubo International Biotech Ltd is a U.S.-listed holding company whose operating business is conducted in China through Yubo International Biotech (Beijing) Limited and related contractual arrangements. The business focuses on endometrial stem cell research and application, and markets a mix of healthcare products and stem cell-related services under the VIVCELL brand.
−8 258,0 %
66,1 %
−8 736,7 %
+256,0 %
0.24
0.23
| % | |
|---|---|
| Stem cell research and services | 20% Research, testing, and consulting services centered on endometrial stem cells. |
| Respiratory healthcare products | 20% Consumer healthcare products positioned for respiratory wellness and related care. |
| Skincare and hair care products | 20% Beauty and personal care products sold under the VIVCELL brand. |
| Healthy beverages | 15% Functional beverage products marketed as part of the wellness portfolio. |
| Personal care products | 15% Male and female personal care products tied to the company’s consumer health offering. |
| Health management consulting | 10% Consulting services related to health management and cell-related wellness. |
The company sells to a small number of customers, with historical revenue concentrated in a limited customer base in...
- Consumer wellness customersprimary
Buy branded healthcare, skincare, hair care, beverage, and personal care products for everyday use.
- Stem cell service clientssecondary
Use cell testing and health management consulting tied to the company’s stem cell platform.
- Wholesale/distribution customersprimary
Purchase product inventory or act as channel partners for the VIVCELL brand in China.
Yubo International Biotech is a U.S. holding company, but its operating activities are centered in Beijing, China...
- •U.S.-listed holding company with operating business in China
- •Principal executive offices are in Beijing, China
- •Day-to-day operations are conducted through Yubo Beijing
- •Chinese licenses and approvals are required to operate
- •Geographic exposure is concentrated in mainland China
The company’s strategy is centered on building its stem cell platform while commercializing a broader VIVCELL-branded...
01
Advance the stem cell platformmedium-term
The company’s differentiation depends on its endometrial stem cell research and related services.
02
Commercialize consumer wellness productsshort-term
Product sales provide a broader market beyond specialized stem cell services.
03
Preserve China operating accessshort-term
The business depends on PRC licenses, approvals, and contractual arrangements with the VIE.
The company faces concentration risk because historical revenue has come from a limited number of customers, and recent...
Operating and regulatory risk in China
The business requires PRC licenses and approvals to operate and is subject to local regulatory oversight.
- Scope
- Beijing operating entity and PRC permits
- Materiality
- high
VIE structure and contractual control risk
The listed parent does not directly own the PRC operating company, so control depends on contractual arrangements.
- Scope
- Yubo Beijing VIE structure
- Materiality
- high
Product and compliance risk
Healthcare, personal care, and food-related products can face quality, labeling, and regulatory compliance issues.
- Scope
- Food Operation License Permit and medical distribution filing
- Materiality
- medium
Fair value measurements
Valuation assumptions can change earnings and balance sheet values
Earnings per share
Dilution and share structure may distort per-share comparability
Accrued expenses and contingencies
Expense recognition may shift between periods
VIE consolidation and related-party arrangements
Consolidation judgments affect what assets, liabilities, and revenue are reported
: 29.4.2026